Development, validation and clinical assessment of a short questionnaire to assess disease-related knowledge in inflammatory bowel disease patients

Keegan, Denise; McDermott, Edel; Byrne, Kathryn R.; Moloney, David; Doherty, Glen; Mulcahy, Hugh

doi:10.3109/00365521.2012.744090

Cited by 19 publications

(12 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Participants were recruited to four groups: children with IBD, children without IBD, medical staff, and administrative staff. These groups have previously been established as having hierarchical levels of IBD knowledge with medical staff scoring highest, followed by IBD patients, administrative/clerical staff, and the control group of children without IBD scoring lowest [10,12,16,17].…”

Section: Methodsmentioning

confidence: 99%

“…Following the revisions to IBD-KID, it was important to determine whether IBD-KID2 performed as well as the original in providing an overall assessment of diseasespecific knowledge and in highlighting deficient areas. IBD-KID2 was validated using a process similar to the original IBD-KID and other knowledge assessment tools [10,16,17], whereby it was administered to four groups of participants whose knowledge levels have been empirically established. Reliability was assessed using test-retest assessments and internal consistency.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Validation of a Revised Knowledge Assessment Tool for Children with Inflammatory Bowel Disease (IBD-KID2)

Vernon‐Roberts¹,

Otley²,

Frampton³

et al. 2020

Inflamm Intest Dis

View full text Add to dashboard Cite

Introduction: For children with inflammatory bowel disease (IBD), acquired knowledge of their condition and treatment is integral to their adherence and self-management. Assessing their knowledge is vital to identify deficits that may affect disease management. IBD-KID2 is a knowledge assessment tool written for children aged 8 years and over with IBD. Objectives: In order to examine validity and reliability, a study was carried out using IBD-KID2 in a paediatric IBD population and a number of comparator groups with established levels of IBD knowledge. Methods: IBD-KID2 was administered to 4 participant groups in Christchurch Hospital, New Zealand: children with IBD (n = 22), children without IBD (n = 20), medical staff (n = 15), and administration staff (n = 15). Between-group differences were tested using ANOVA and pairwise comparisons made with the IBD group. Repeat assessments by the IBD group determined test-retest reliability (n = 21). Results: The mean age (range) of the paediatric groups were: IBD 13.3 years (8-18), without IBD 11.9 years (8-15). Group mean scores (SD) were: IBD 8.5 (±2.3), without IBD 3.7 (±2.2), medical staff 13.5 (±1.3), administration staff 6.3 (±2.5). Group means were all significantly different to the IBD group. Testretest mean at baseline (8.4, CI ±2.4) and repeat (9.0, CI ±2.4) were not significant. Intraclass correlation coefficient was 0.82. Internal reliability was 0.85, and item-total statistics showed no improvement by specific item removal. Conclusions: IBD-KID2 could distinguish between groups with different knowledge levels. Repeat assessment shows comparable scores on retest and good reproducibility. IBD-KID2 is a valid and reliable tool for use in the paediatric IBD population.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Validation of a Revised Knowledge Assessment Tool for Children with Inflammatory Bowel Disease (IBD-KID2)

Vernon‐Roberts¹,

Otley²,

Frampton³

et al. 2020

Inflamm Intest Dis

View full text Add to dashboard Cite

show abstract

“…23 24 Disease-related patient knowledge was measured with the short IBD knowledge questionnaire. 25 Patients were asked to rate how acceptable a treat to target approach was to them on 10-point Likert scales. In accordance with adherence studies (cut-off usually 80%) we determined that a Likert scale rating of ≥8 represented acceptance of a treat to target approach.…”

Section: Questionnairesmentioning

confidence: 99%

Acceptability of a ‘treat to target’ approach in inflammatory bowel disease to patients in clinical remission

Selinger

Carbonell

Kane

et al. 2020

Frontline Gastroenterol

View full text Add to dashboard Cite

BackgroundA ‘treat to target’ approach aiming for remission of clinical symptoms and absence of mucosal inflammation has been proposed in inflammatory bowel disease (IBD). We aimed to establish whether patients with IBD in clinical remission find this approach acceptable.MethodsPatients in glucocorticosteroid-free clinical remission underwent a face-to-face structured, quantitative interview and rated the acceptability of treat to target on a 10-point Likert scale. We analysed factors associated with agreement to treat to target.ResultsThe cohort comprised 298 patients (144 Crohn’s disease, 136 ulcerative colitis, 18 IBD-unclassified). Elevated C-reactive protein was found in 24.4% and elevated faecal calprotectin in 17.7%. Overall, 66.2% of patients rated a treat to target approach as acceptable (Likert scale ≥8). Acceptable treatment aims for patients were avoidance of flare, hospitalisation, surgery and colorectal cancer. Using binary logistic regression analysis the following were not predictive of accepting a treat to target approach: age, diagnosis, disease phenotype, surgical history, disease duration, patient knowledge, adherence, anxiety, depression and patient-reported control of disease. Better adherence to current therapy was associated with accepting a treat to target approach (B=0.16, p=0.039).ConclusionIn a cohort of patients in clinical remission, where this strategy is most relevant, two-thirds of patients agreed with treat to target. Patients with better current adherence were more likely to accept treat to target. Patient education and counselling materials will need to be developed to convince a substantial minority of patients of the importance of treat to target.

show abstract

“…Andere Untersuchungen zum Einfluss des SoS auf das Krankheitswissen bei Kindern mit einer chronischen Erkrankung liegen unseres Wissens bisher nicht vor. In einer Untersuchung von Keegan konnte bei Erwachsenen mit chronisch entzündlichen Darmerkrankungen eine positive Korrelation zwischen dem SoS und dem Krankheitswissen aufgezeigt werden [26]. Das niedrige Krankheitswissen könnte miterklären, weshalb sich ein niedriger SoS negativ auf den Verlauf einer chronischen Erkrankung im Kindesalter auswirkt [9].…”

Section: Krankheitswissenunclassified

Wie beeinflussen psychosoziale Risiken den Erfolg von Patientenschulungen in der Pädiatrie?

et al. 2017

View full text Add to dashboard Cite

show abstract

Development, validation and clinical assessment of a short questionnaire to assess disease-related knowledge in inflammatory bowel disease patients

Abstract: The short knowledge questionnaire is a simple, valid, reliable and easy to understand research instrument for rapidly assessing knowledge in IBD patients.

Cited by 19 publications

References 22 publications

Validation of a Revised Knowledge Assessment Tool for Children with Inflammatory Bowel Disease (IBD-KID2)

Validation of a Revised Knowledge Assessment Tool for Children with Inflammatory Bowel Disease (IBD-KID2)

Acceptability of a ‘treat to target’ approach in inflammatory bowel disease to patients in clinical remission

Wie beeinflussen psychosoziale Risiken den Erfolg von Patientenschulungen in der Pädiatrie?

Contact Info

Product

Resources

About